These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 16293698)

  • 1. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice.
    Clément-Lacroix P; Ai M; Morvan F; Roman-Roman S; Vayssière B; Belleville C; Estrera K; Warman ML; Baron R; Rawadi G
    Proc Natl Acad Sci U S A; 2005 Nov; 102(48):17406-11. PubMed ID: 16293698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/beta-catenin signaling, osteoblast function, and bone formation.
    Haÿ E; Laplantine E; Geoffroy V; Frain M; Kohler T; Müller R; Marie PJ
    Mol Cell Biol; 2009 Feb; 29(4):953-64. PubMed ID: 19075000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.
    Sawakami K; Robling AG; Ai M; Pitner ND; Liu D; Warden SJ; Li J; Maye P; Rowe DW; Duncan RL; Warman ML; Turner CH
    J Biol Chem; 2006 Aug; 281(33):23698-711. PubMed ID: 16790443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wnt-Lrp5 signaling regulates fatty acid metabolism in the osteoblast.
    Frey JL; Li Z; Ellis JM; Zhang Q; Farber CR; Aja S; Wolfgang MJ; Clemens TL; Riddle RC
    Mol Cell Biol; 2015 Jun; 35(11):1979-91. PubMed ID: 25802278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
    Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
    J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lithium chloride attenuates BMP-2 signaling and inhibits osteogenic differentiation through a novel WNT/GSK3- independent mechanism.
    Li J; Khavandgar Z; Lin SH; Murshed M
    Bone; 2011 Feb; 48(2):321-31. PubMed ID: 20932949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling.
    Balemans W; Devogelaer JP; Cleiren E; Piters E; Caussin E; Van Hul W
    J Bone Miner Res; 2007 May; 22(5):708-16. PubMed ID: 17295608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone.
    Williams BO; Insogna KL
    J Bone Miner Res; 2009 Feb; 24(2):171-8. PubMed ID: 19072724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt signaling control of bone cell apoptosis.
    Bodine PV
    Cell Res; 2008 Feb; 18(2):248-53. PubMed ID: 18212734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop.
    Rawadi G; Vayssière B; Dunn F; Baron R; Roman-Roman S
    J Bone Miner Res; 2003 Oct; 18(10):1842-53. PubMed ID: 14584895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro.
    Spencer GJ; Utting JC; Etheridge SL; Arnett TR; Genever PG
    J Cell Sci; 2006 Apr; 119(Pt 7):1283-96. PubMed ID: 16522681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling.
    Rhee Y; Allen MR; Condon K; Lezcano V; Ronda AC; Galli C; Olivos N; Passeri G; O'Brien CA; Bivi N; Plotkin LI; Bellido T
    J Bone Miner Res; 2011 May; 26(5):1035-46. PubMed ID: 21140374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.
    Gong Y; Slee RB; Fukai N; Rawadi G; Roman-Roman S; Reginato AM; Wang H; Cundy T; Glorieux FH; Lev D; Zacharin M; Oexle K; Marcelino J; Suwairi W; Heeger S; Sabatakos G; Apte S; Adkins WN; Allgrove J; Arslan-Kirchner M; Batch JA; Beighton P; Black GC; Boles RG; Boon LM; Borrone C; Brunner HG; Carle GF; Dallapiccola B; De Paepe A; Floege B; Halfhide ML; Hall B; Hennekam RC; Hirose T; Jans A; Jüppner H; Kim CA; Keppler-Noreuil K; Kohlschuetter A; LaCombe D; Lambert M; Lemyre E; Letteboer T; Peltonen L; Ramesar RS; Romanengo M; Somer H; Steichen-Gersdorf E; Steinmann B; Sullivan B; Superti-Furga A; Swoboda W; van den Boogaard MJ; Van Hul W; Vikkula M; Votruba M; Zabel B; Garcia T; Baron R; Olsen BR; Warman ML;
    Cell; 2001 Nov; 107(4):513-23. PubMed ID: 11719191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
    Li X; Zhang Y; Kang H; Liu W; Liu P; Zhang J; Harris SE; Wu D
    J Biol Chem; 2005 May; 280(20):19883-7. PubMed ID: 15778503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.
    Levasseur R; Lacombe D; de Vernejoul MC
    Joint Bone Spine; 2005 May; 72(3):207-14. PubMed ID: 15850991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor.
    Kato M; Patel MS; Levasseur R; Lobov I; Chang BH; Glass DA; Hartmann C; Li L; Hwang TH; Brayton CF; Lang RA; Karsenty G; Chan L
    J Cell Biol; 2002 Apr; 157(2):303-14. PubMed ID: 11956231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt coreceptor Lrp5 is a driver of idiopathic pulmonary fibrosis.
    Lam AP; Herazo-Maya JD; Sennello JA; Flozak AS; Russell S; Mutlu GM; Budinger GR; DasGupta R; Varga J; Kaminski N; Gottardi CJ
    Am J Respir Crit Care Med; 2014 Jul; 190(2):185-95. PubMed ID: 24921217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1,25-Dihydroxyvitamin D3 regulates the expression of low-density lipoprotein receptor-related protein 5 via deoxyribonucleic acid sequence elements located downstream of the start site of transcription.
    Fretz JA; Zella LA; Kim S; Shevde NK; Pike JW
    Mol Endocrinol; 2006 Sep; 20(9):2215-30. PubMed ID: 16613987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass.
    Ferrari SL; Deutsch S; Antonarakis SE
    Curr Opin Lipidol; 2005 Apr; 16(2):207-14. PubMed ID: 15767861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Very low density lipoprotein receptor, a negative regulator of the wnt signaling pathway and choroidal neovascularization.
    Chen Y; Hu Y; Lu K; Flannery JG; Ma JX
    J Biol Chem; 2007 Nov; 282(47):34420-8. PubMed ID: 17890782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.